Phase 2 Study of Upadacitinib (RINVOQ®) Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus

- At week 24, upadacitinib 30 mg given alone or as a combination therapy (ABBV-599 high dose [elsubrutinib 60 mg and upadacitinib 30 mg]) met the primary...

Related Keywords

Japan ,Oklahoma ,United States ,Japanese ,Joan Merrill ,Roopal Thakkar ,Upadacitinib Monotherapy ,Linkedin ,Arthritis Clinical Immunology Research Program ,Centers For Disease ,European Congress ,Lupus Erythematosus National Assessment ,Exchange Commission ,Oklahoma Medical Research Foundation ,Twitter ,Facebook ,Abbvie Deutschland Gmbh Co ,Instagram ,British Isles Lupus Assessment Group ,Responder Index ,Lupus Low Disease Activity State ,Flare Index ,Clinical Immunology Research ,Allergan Aesthetics ,Private Securities Litigation Reform Act ,Quarterly Reports ,Final Lock ,Key Results ,Intended Indication ,Systemic Lupus Erythematosus ,Adult Systemic Lupus Erythematosus ,Disease Activity ,Arthritis Care Res ,Disease Control ,Accessed April ,Vie Deutschland Gmbh ,Severely Active Ulcerative ,Maintenance Therapy ,Severely Active Ulcerative Colitis ,Takayasu Arteritis ,Evaluate Efficacy ,Adult Participants ,Ann Rheum ,Giant Cell ,Abbvie ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Pharmaceuticals ,Biotechnology ,Trade Show News ,Clinical Trials Amp Medical Discoveries ,